Validation of a numerical rating scale to assess functional impairment in hip and knee osteoarthritis: Comparison with the WOMAC function scale

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 740-746

  Ornetti, Paul ^a,b,c   Dougados, Maxime ^c   Paternotte, Simon ^c   Logeart, Isabelle ^d,e   Gossec, Laure ^c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Dohme Chibret Centre de Recherche Riom   (France)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEASIBILITY STUDY; FEMALE; FRANCE; FUNCTIONAL ASSESSMENT; HIP OSTEOARTHRITIS; HUMAN; INTERMETHOD COMPARISON; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUMERICAL RATING SCALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; RATING SCALE; SELF REPORT; TREATMENT RESPONSE; VALIDATION STUDY; VISUAL ANALOG SCALE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

AGED; DISABILITY EVALUATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX;

EID: 79953331927     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.135483     Document Type: Article

References (39)

1. U.S. Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures:Use in Medical Product Development to Support Labeling Claims. 2009.
2. Dawson J, Doll H, Fitzpatrick R, et al. The routine use of patient reported outcome measures in healthcare settings. BMJ 2010;340:c186.
3. Dougados M. Monitoring osteoarthritis progression and therapy. Osteoarthr Cartil 2004;12 Suppl A:S55-60.
4. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis 1996;55:552-7.
5. Altman R, Brandt K, Hochberg M, et al. Design and conduct of clinical trials in patients with osteoarthritis:recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthr Cartil 1996;4:217-43. (Pubitemid 26408292)
6. Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799-802. (Pubitemid 27146105)
7. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited Osteoarthr Cartil 2004;12:389-99.
8. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40. (Pubitemid 19037656)
9. Guyatt GH, Townsend M, Berman LB, et al. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 1987;40:1129-33. (Pubitemid 17158144)
10. Bellamy N, Muirden KD, Brooks PM, et al. A survey of outcome measurement procedures in routine rheumatology outpatient practice in Australia. J Rheumatol 1999;26:1593-9. (Pubitemid 29317885)
11. Gossec L, Dougados M, Rincheval N, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
12. Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 2005;32:1261-6. (Pubitemid 40995380)
13. Tubach F, Wells GA, Ravaud P, et al. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol 2005;32:2025-9. (Pubitemid 41429037)
14. Kvien TK, Heiberg T, Hagen KB. Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? Ann Rheum Dis 2007;66:iii40-1.
15. Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007;34:1188-93. (Pubitemid 46774873)
16. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33. (Pubitemid 40075270)
17. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005;64:34-7. (Pubitemid 40075271)
18. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
19. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
20. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
21. Choquette D, Bellamy N, Raynauld J. A French-Canadian version of the WOMAC osteoarthritis index. Arthritis Rheum 1994;37:S226.
22. Ornetti P, Parratte S, Gossec L, et al. Cross-cultural adaptation and validation of the French version of the Knee injury and Osteoarthritis Outcome Score (KOOS) in knee osteoarthritis patients. Osteoarthr Cartil 2008;16:423-8. (Pubitemid 351444568)
23. Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003;30:877-9. (Pubitemid 36402792)
24. Husted JA, Cook RJ, Farewell VT, et al. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459-68. (Pubitemid 30254341)
25. Baron G, Tubach F, Ravaud P, et al. Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis. Arthritis Rheum 2007;57:633-8. (Pubitemid 46764054)
26. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001;45:453-61. (Pubitemid 32979851)
27. Bellamy N, Kean WF, Buchanan WW, et al. Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. J Rheumatol 1992;19:153-9.
28. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999;19:1269-78.
29. Hawker GA. Experiencing painful osteoarthritis: what have we learned from listening? Curr Opin Rheumatol 2009;21:507-12.
30. Dougados M, Leclaire P, van der Heijde D, et al. Response criteria for clinical trials on osteoarthritis of the knee and hip:a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthr Cartil 2000;8:395-403. (Pubitemid 32000962)
31. Bellamy N. Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Osteoarthr Cartil 1999;7:424-6.
32. Tubach F, Dougados M, Falissard B, et al. Feeling good rather than feeling better matters more to patients. Arthritis Rheum 2006;55:526-30. (Pubitemid 44289869)
33. Pincus T, Askanase AD, Swearingen CJ. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin North Am 2009;35:819-27, x.
34. Pincus T. Why should rheumatologists collect patient self-report questionnaires in routine rheumatologic care? Rheum Dis Clin North Am 1995;21:271-319.
35. Lohr KN, Zebrack BJ. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual Life Res 2009;18:99-107.
36. Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol 2007;21:601-28. (Pubitemid 47189089)
37. Yang KG, Raijmakers NJ, Verbout AJ, et al. Validation of the short-form WOMAC function scale for the evaluation of osteoarthritis of the knee. J Bone Joint Surg Br 2007;89:50-6. (Pubitemid 46218412)
38. Perruccio AV, Stefan Lohmander L, Canizares M, et al. The development of a short measure of physical function for knee OA KOOS-Physical Function Shortform (KOOS-PS)-an OARSI/OMERACT initiative. Osteoarthr Cartil 2008;16:542-50.
39. Davis AM, Perruccio AV, Canizares M, et al. Comparative, validity and responsiveness of the HOOS-PS and KOOS-PS to the WOMAC physical function subscale in total joint replacement for osteoarthritis. Osteoarthr Cartil 2009;17:843-7.